Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCC-2618 versus sunitinib after imatinib in advanced GIST
NL-OMON54739Phase 3Recruiting
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Nov 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing DCC-2618 with sunitinib (2 arms). Primary endpoint: Progression-free survival. Started Nov 2019; status: recruiting.
02
Drugs
ripretinibsunitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON54739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54739.